secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001193125-22-211873
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Q2 net loss $17.3M; cash $139.4M; MGTA-117 interim data expected Q4 2022
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $139.4M as of June 30, 2022; funds operations into Q2 2024.
- Net loss of $17.3M in Q2 2022 vs. $16.9M in Q2 2021; R&D expenses $11.6M, G&A $6.5M.
- MGTA-117 Phase 1/2 trial progressing; interim clinical data from multiple dose cohorts on track for Q4 2022.
- CD45-ADC IND-enabling studies ongoing; in-life toxicology complete; program update expected Q4 2022.
- MGTA-145 stem cell mobilization trial in sickle cell disease initiated; initial data anticipated Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522211873/0001193125-22-211873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522211873/d390658d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-211873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer